A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus

In a double-blind, placebo-controlled, phase 3 trial, patients undergoing hemodialysis who had moderate-to-severe pruritus were randomly assigned to receive the selective kappa opioid receptor agonist difelikefalin or placebo for 12 weeks. Difelikefalin significantly reduced itch intensity and impro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-01, Vol.382 (3), p.222-232
Hauptverfasser:	Fishbane, Steven, Jamal, Aamir, Munera, Catherine, Wen, Warren, Menzaghi, Frédérique
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Body weight Diarrhea Double-Blind Method Female Hemodialysis Humans Intravenous administration Kidney diseases Kidney Failure, Chronic - complications Kidney Failure, Chronic - therapy Male Middle Aged Narcotics Opioid receptors (type kappa) Patient safety Piperidines - adverse effects Piperidines - therapeutic use Pruritus Pruritus - drug therapy Pruritus - etiology Quality of Life Questionnaires Receptors, Opioid - agonists Renal Dialysis Treatment Outcome Uremia - complications Vomiting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a double-blind, placebo-controlled, phase 3 trial, patients undergoing hemodialysis who had moderate-to-severe pruritus were randomly assigned to receive the selective kappa opioid receptor agonist difelikefalin or placebo for 12 weeks. Difelikefalin significantly reduced itch intensity and improved quality of life as compared with placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1912770